The company said, “The most significant corporate highlight of the year was the receipt of FDA 510(k) clearance in August 2025 for Daxor’s (DXR) next-generation rapid, compact, and portable Blood Volume Analyzer. Developed under contract with the U.S. Department of Defense. This new system delivers laboratory-grade diagnostic precision three times faster than previous models. The company is currently utilizing newly raised capital to assemble these next-generation units for placement while expanding its commercial sales team to meet enthusiastic market response.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DXR:
- Daxor continues strategic expansion, opens new BVA program in Tennessee
- Daxor initiated with a Buy at Lake Street
- Daxor to transition to Securities Exchange Act of 1934 reporting company
- Daxor Files Legal Opinion Affirming Validity of Stock
- Daxor prices 765,958 shares at $11.75 in registered direct offering